Mahmoud Mosli1, Turki Alameel2, Ala I Sharara3. 1. Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. 2. Department of Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia. 3. Division of Gastroenterology, Department of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Abstract
BACKGROUND: Crohn's disease is a progressive inflammatory bowel disease. Persistent untreated inflammation can cumulatively result in bowel damage in the form of strictures, fistulas, and fibrosis, which can ultimately result in the need for major abdominal surgery. Mucosal healing has emerged as an attractive, yet ambitious goal in the hope of preventing long-term complications. SUMMARY: Clinical remission is an inadequate measure of disease activity. Noninvasive markers such as fecal calprotectin, CRP, or small bowel ultrasound are useful adjunct tools. However, endoscopic assessment remains the cornerstone in building a treatment plan. Achieving complete mucosal healing has proved to be an elusive goal even in the ideal setting of a clinical trial. KEY MESSAGES: Aiming for complete mucosal healing in all patients may result in overuse of medications, higher costs, and potential side effects of aggressive immunosuppressive treatment. More practical goals such as relative or partial healing, for example, 50% improvement in inflammation and reduction in size of ulcers, ought to be considered, particularly in difficult-to-treat populations.
BACKGROUND: Crohn's disease is a progressive inflammatory bowel disease. Persistent untreated inflammation can cumulatively result in bowel damage in the form of strictures, fistulas, and fibrosis, which can ultimately result in the need for major abdominal surgery. Mucosal healing has emerged as an attractive, yet ambitious goal in the hope of preventing long-term complications. SUMMARY: Clinical remission is an inadequate measure of disease activity. Noninvasive markers such as fecal calprotectin, CRP, or small bowel ultrasound are useful adjunct tools. However, endoscopic assessment remains the cornerstone in building a treatment plan. Achieving complete mucosal healing has proved to be an elusive goal even in the ideal setting of a clinical trial. KEY MESSAGES: Aiming for complete mucosal healing in all patients may result in overuse of medications, higher costs, and potential side effects of aggressive immunosuppressive treatment. More practical goals such as relative or partial healing, for example, 50% improvement in inflammation and reduction in size of ulcers, ought to be considered, particularly in difficult-to-treat populations.
Authors: Filip Baert; Liesbeth Moortgat; Gert Van Assche; Philip Caenepeel; Philippe Vergauwe; Martine De Vos; Pieter Stokkers; Daniel Hommes; Paul Rutgeerts; Severine Vermeire; Geert D'Haens Journal: Gastroenterology Date: 2009-10-08 Impact factor: 22.682
Authors: Geert DʼHaens; Walter Reinisch; Remo Panaccione; Jack Satsangi; Joel Petersson; Mareike Bereswill; Dilek Arikan; Eva Perotti; Anne M Robinson; Jasmina Kalabic; Gabriela Alperovich; Roopal Thakkar; Edward V Loftus Journal: Am J Gastroenterol Date: 2018-06-05 Impact factor: 10.864
Authors: Walter Reinisch; Krisztina Gecse; Jonas Halfvarson; Peter M Irving; Jørgen Jahnsen; Laurent Peyrin-Biroulet; Gerhard Rogler; Stefan Schreiber; Silvio Danese Journal: Inflamm Bowel Dis Date: 2021-01-01 Impact factor: 5.325
Authors: Peter D R Higgins; Gale Harding; Nancy K Leidy; Kendra DeBusk; Donald L Patrick; Hema N Viswanathan; Kristina Fitzgerald; Sarah M Donelson; Marcoli Cyrille; Brian G Ortmeier; Hilary Wilson; Dennis A Revicki; Gary Globe Journal: J Patient Rep Outcomes Date: 2018-05-09